Healthy
Conditions
Keywords
resistant starch, short-chain fatty acids, gut microbiota, peripheral chemoreflex, arterial baroreflex, autonomic nervous system
Brief summary
Recent data feature short-chain fatty acids (SCFAs), products of gut microbial fermentation, as modulators of the blood pressure of the host. Such modulation may evoke (or arise from) changes in the autonomic reflexive mechanisms, but the link remains unexplored. Therefore, the study aims to explore potential relationship between the dietary intervention-induced changes in the SCFA plasma/fecal content and alterations in the sensitivity of the cardio-respiratory autonomic reflexes. In this cross-over, placebo-controlled study, a group of healthy volunteers will undergo three distinct stages of a four-week dietary intervention, separated by at least two weeks of washout periods. During each stage, participants will receive one of the following interventions: * raw potato starch (a source of resistant type 2 starch, which is a substrate for the endogenous production of SCFAs) * sodium butyrate (a direct, exogenous source of this SCFA) * an amylase-accessible waxy maze starch (a placebo). Plasma and fecal SCFA concentrations will be measured, along with the comprehensive evaluation of the cardio-respiratory parameters and the sensitivity of the autonomic reflexive mechanisms.
Interventions
DIETARY_SUPPLEMENTPotato starch supplementation
Participants will receive potato starch supplement, undergoing gut microbial fermentation and acting as an endogenous source of the short-chain fatty acids, including butyrate. Effects of these compounds on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
DIETARY_SUPPLEMENTSodium butyrate supplementation
Participants will receive sodium butyrate supplement, acting as an exogenous source of the short-chain fatty acid butyrate. Effects of such compound on the selected autonomic functions (i.e. cardio-respiratory control) will be further investigated.
DIETARY_SUPPLEMENTAccessible starch supplementation
Participants will receive the accessible (digestible) waxy maze starch as placebo.
Sponsors
Wroclaw Medical University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* age 18-40 years
Exclusion criteria
* chronic disease of the nervous, cardiovascular or respiratory system * disease of the digestive system, including history of the intestinal surgery, inflammatory bowel disease, celiac disease, lactose intolerance and other malabsorption disorders * blood pressure-lowering treatment within the past year * tobacco smoking within the past year * antibiotic/probiotic treatment and laxative/prokinetic usage in three months preceding the anticipated enrollment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Arterial baroreflex sensitivity | From the beginning to the end of a supplementation period at 4 weeks. | Arterial baroreflex sensitivity, measured with a neck chamber technique. |
| Peripheral chemoreflex sensitivity | From the beginning to the end of a supplementation period at 4 weeks. | Peripheral chemoreflex sensitivity, measured with the transient hypoxia test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma short-chain fatty acids | From the beginning to the end of a supplementation period at 4 weeks. | Plasma level of short-chain fatty acids, evaluated with high-performance liquid chromatography. |
Countries
Poland
Outcome results
None listed